Opioid abuse has been declared a public
Pain medications are essential for improving the care and outcomes for the 100 million adults
living with chronic pain in the United States.
And yet, more than 130 people die every day from opioid-related overdoses.
Meanwhile the cost of medical treatment and lost productivity associated with chronic pain is
estimated at $560-$635 billion annually.
Ensysce intends to launch the first new
class of Opioid analgesics in decades —
limiting the chances for abuse
while alleviating pain
We’re a biotech company committed to stemming the prescription drug abuse epidemic.
Our proprietary prodrug technologies: abuse resistant TAAP™ and overdose resistant MPAR™
are designed to improve the care of patients with chronic pain while reducing the human
and economic costs associated with prescription drug abuse.
Ensysce is disrupting the field of abuse
and overdose with its prodrug approach
Ensysce is developing a proprietary abuse-resistant prodrug technology called TAAP™
a highly novel platform that eliminates the possibility for abuse by snorting,
extracting, injection or chewing.
TAAP™-opioids have the potential to meet the medical needs of patients living with chronic pain,
while providing a solution to the national epidemic of prescription opioid abuse, limiting their use
to oral administration.
In addition, our unique Multi-Pill Abuse Resistant technology MPAR™ provides another layer
of protection, eliminating the possibility of overdose.
Together TAAP™ and MPAR™ are designed to work in conjunction,
both to overcome abuse and — ultimately — to save lives.
Our proprietary technology
has applications beyond just opioids
In addition to working with all known prescription opioid drugs, our abuse-resistant drug technologies
TAAP™ and MPAR™ have broad potential across a variety of other drugs with the possibility of abuse.
For example, we currently have multiple TAAP™ products in the pipeline including one for ADHD.
The FDA granted Fast Track designation for
TAAP™-PF614 in January 2018
TAAP™-PF614 is a proprietary prodrug of oxycodone and our lead abuse-resistant opioid drug. We have made it our priority program due to the crisis of opioid abuse and the urgent need for a more abuse-resistant form of this important pain therapy.
To imagine the impossible
takes both brilliant minds and a vision.
We’re proud to say our team is made up of just that — people and minds both driven by passion
and full of potential. Our company is led by a team of executives and directors with vast experience
and proven track records in pain, drug development and commercialization.